Background: Intrahepatic cholangiocarcinoma (CCA) is an aggressive cancer which still lacks of effective targeted therapy. Regorafenib is an oral inhibitor of multi-kinases which had been approved for treating patients with end-stage hepatoma, but the role of this drug in CCA therapy has not yet been reported. Methods: Here, we performed in vitro and in vivo studies evaluating the regorafenib in CCA. In silico methods were performed to explore the novel molecular mechanism of regororafenib and to potentially identify biomarkers in CCA. Results: We first demonstrated that regorafenib not only inhibited the growth but also induced the apoptosis in CCA cells. Subsequently, we identified in silico MALT1 (Mucosa-associated lymphoid tissue protein 1) which plays an important role in activating NF-kB as a potential target of regorafenib. Next, overexpression of Elk-1 but not Ets-1 in HuCCT1 cell markedly reduced their sensitivity to regorafenib which might be attributed to a significant increase of MALT1 and our results further demonstrated that this drug drastically inhibited MALT1 expression by suppressing the RAF/ERK/Elk-1 pathway.To no surprise, the efficacies of regorafenib in decreasing the in vivo growth of CCA were confirmed. The efficacy of regorafenib was observed in two MALT1-positive CCA patients who failed for several lines therapy. Finally, MALT1 was also identified as an independent poor prognostic factor for patients with intrahepatic CCA. Conclusions: Our study identified MALT1 to be a downstream mediator of the RAF/ ERK/Elk-1 pathway which may be a new therapeutic target for successful treatment of CCA by regorafenib. Background: Gemcitabine(GEM)þnab-Paclitaxel(nab-PTX) is one of the standard therapy for patients with advanced or recurrent pancreatic cancer. Because only 10% of patients were elderly, 75 years or older, in the phase III trial of GEMþnab-PTX, the efficacy and safety of this combination therapy have been unclear in an elderly patient. To assess the efficacy and safety of GEMþnab-PTX in elderly patients, we retrospectively analyzed clinical data in elderly patients compared with non-elderly patients. Methods: We collected clinical data of patients with advanced or recurrent pancreatic cancer primarily treated with GEMþnab-PTX in our hospital from December 2014 to December 2016, and divided into the elderly group (75years old or older) and nonelderly group (under 75 years old). Results:Twenty-eight patients were treated with GEMþnab-PTX. 13 patients were elderly group [Median age,[78][79][80][81][82][83][84][85][86]]and 15 patients were non-elderly group [Median age,[69][70][71][72][73]]. The background characteristics (sex, PS, complications, etc.) were not different between two groups. Three patients were started initial therapy with dose reduction, and all of them were in elderly group. The efficacy was comparable between elderly group and non-elderly group (1 year survival rate: 50.8% vs. 57.0%, P ¼ 0.75). Grade 3 or higher adverse events were observed in 8 patients (61%) of elderly group and 7 patients (47%) of non-elderly group. One early death after treatment was observed in the elderly group, that might be related with underlying disease. Conclusion: The efficacy and safety profile of GEMþnab-PTX in elderly patients seemed to be comparable with non-elderly patients. However, we experienced one early death after treatment in elderly patient. Therefore, it would be better to be more careful for deciding the indication and initial doses of GEMþnab-PTX in elderly patients. Background: Gemcitabine plus nab-Paclitaxel (GnP) has been one of the standard first-line therapy in patient with advanced pancreatic cancer. In order to improve the prognosis of such patients, there is an urgent need to establish an effective second-line therapy. Although various second-line therapies have been studied, any phase III data do not support a particular regimen. In Japan, S-1 is commonly used for the treatment of pancreatic cancer patients. But there were few reports about S-1 as the second line treatment of pancreatic cancer patients who failed GnP treatment. Objectives: To evaluate the efficacy and safety of S-1 in patients with GnP-refractory pancreatic cancer as a second-line setting.
Background: Gemcitabine(GEM)þnab-Paclitaxel(nab-PTX) is one of the standard therapy for patients with advanced or recurrent pancreatic cancer. Because only 10% of patients were elderly, 75 years or older, in the phase III trial of GEMþnab-PTX, the efficacy and safety of this combination therapy have been unclear in an elderly patient. To assess the efficacy and safety of GEMþnab-PTX in elderly patients, we retrospectively analyzed clinical data in elderly patients compared with non-elderly patients. Methods: We collected clinical data of patients with advanced or recurrent pancreatic cancer primarily treated with GEMþnab-PTX in our hospital from December 2014 to December 2016, and divided into the elderly group (75years old or older) and nonelderly group (under 75 years old). Results:Twenty-eight patients were treated with GEMþnab-PTX. 13 patients were elderly group [Median age, [78] [79] [80] [81] [82] [83] [84] [85] [86] ]and 15 patients were non-elderly group [Median age, [69] [70] [71] [72] [73] ]. The background characteristics (sex, PS, complications, etc.) were not different between two groups. Three patients were started initial therapy with dose reduction, and all of them were in elderly group. The efficacy was comparable between elderly group and non-elderly group (1 year survival rate: 50.8% vs. 57.0%, P ¼ 0.75). Grade 3 or higher adverse events were observed in 8 patients (61%) of elderly group and 7 patients (47%) of non-elderly group. One early death after treatment was observed in the elderly group, that might be related with underlying disease. Conclusion: The efficacy and safety profile of GEMþnab-PTX in elderly patients seemed to be comparable with non-elderly patients. However, we experienced one early death after treatment in elderly patient. Therefore, it would be better to be more careful for deciding the indication and initial doses of GEMþnab-PTX in elderly patients.
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Background: Gemcitabine plus nab-Paclitaxel (GnP) has been one of the standard first-line therapy in patient with advanced pancreatic cancer. In order to improve the prognosis of such patients, there is an urgent need to establish an effective second-line therapy. Although various second-line therapies have been studied, any phase III data do not support a particular regimen. In Japan, S-1 is commonly used for the treatment of pancreatic cancer patients. But there were few reports about S-1 as the second line treatment of pancreatic cancer patients who failed GnP treatment. Objectives: To evaluate the efficacy and safety of S-1 in patients with GnP-refractory pancreatic cancer as a second-line setting.
Patients and Method: Patients with confirmed progressive disease following the firstline treatment with a GnP regimen received S-1 (80/100/120 mg/day based on body surface area (BSA), orally, days 1-28, every 6 weeks). We evaluated retrospectively the efficacy and safety of S-1 in patients with GnP-refractory pancreatic cancer as a secondline setting.
Results: Between January 2015 and December 2016, 19 patients were received S-1 therapy as second line in our hospital. Median age: 68(58-77), Male/Female:10/9, PS 0/1/ 2¼5/11/3, locally advanced/metastatic/reccurence:2/14/3, head/body/tail:8/5/6, number of metastatic sites 0/1/2: 2/11/6, median CA19-9 was 4463. Only one patient was placed biliary stent before first line therapy. Median progression free survival was 3.7 months. Median overall survival was not reached. The response rate was 14%. (CR/PR/ SD/PD/NE:0/2/8/4/3) The major garade3/4 toxicities were leukopenia(5%), neutropenia(5%), anemia(5%) and thrombocytopenia(5%), nausea (5%), vomiting(5%), anorexia(11%), stomatitis(5%) and fatigue(5%). Conclusion: S-1 showed a moderate efficacy with acceptable toxicities for patients with GnP-refractory pancreatic cancer as a second-line setting.
P3 À 089 Risk factors for neutropenia during gemcitabine and nanoparticle albumin-bound paclitaxel combination chemotherapy Background: Gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) combination chemotherapy is a standard of care for unresectable pancreatic cancer. However grade 3 or 4 neutropenia was observed in 38% of the patients in the phase 3 randomized study (MPACT study). Neutropenia often causes the cessation, deferment or dose reduction of GEM þ nab-PTX therapy in our hospital. The aim of this study was to assess risk factors for neutropenia during GEM þ nab-PTX therapy in clinical practice. Methods: We investigated the incidence of neutropenia in patients treated with GEM þ nab-PTX therapy between January 2015 and June 2016 at Kitasato University Hospital. To identify factors associated with grade 3 or 4 neutropenia during the first cycle of GEM þ nab-PTX therapy, we carried out a retrospective study by using cohort of patients without first-dose reduction of GEM or nab-PTX. Results: Of the 75 patients, 51 patients developed grade 3 or 4 neutropenia during the follow-up period. In univariate analysis, low neutrophil count and high serum albumin level before the initiation of therapy were related to grade 3 or 4 neutropenia in 59 patients without first-dose reduction of GEM or nab-PTX. In multivariate analysis, neutrophil counts < 3000/mL (odds ratio: 13.89, p ¼ 0.0004) and serum albumin ! 3.8 g/dL (odds ratio: 5.34, p ¼ 0.0059) before initiation of therapy were identified as the independent risk factors for grade 3 or 4 neutropenia. Conclusion: This study suggested that the occurrence of neutropenia during GEM þ nab-PTX therapy is more frequent in patients with not only low neutrophil count but high serum albumin level before initiation of therapy.
